Category: Health Stock

Buzz

Most Talked About: AVXL – Up 18.44% Today

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] A stock that has been moving up and up lately is Anavex Life Sciences Corp. (OTCQX: AVXL). Shares closed up today 18.44% on very strong volume.  Here is some of what we heard on Twitter Today:    $AVXL Up 0.50 since Thursday entry. This one is almost too easy. Writing was on the wall. We’ll see a 3+ handle post data. Mark it! — Scott Hansen (@peteharmisan) October 5, 2015 We heard this from Matt Duffield on Twitter:  @Duffield84 Just took two months but $AVXL and $AQXP market caps are nearly equal now. — Matt Duffield

Featured

Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech’s Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial

SILVER SPRING, Md., Oct. 05, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article is written by Dr. Ronald L. Korn, MD, Ph.D., who is the Founder, Chairman and Chief Medical Officer of Imaging Endpoints in Scottsdale, Arizona. Imaging Endpoints is the company that will perform

Globe Newswire

Stereotaxis Announces Warrants Offering

ST. LOUIS, Sept. 4, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will conduct a registered offering of subscription warrants to the holders of its common shares, which will function similarly to a rights offering. The Company has declared the record date for determination of stockholders eligible to participate as September 9, 2015 at 5:00 p.m. Eastern Time. At such time, each holder will be issued, at no charge, one subscription warrant for every four common shares held, which will entitle the holder to purchase

Biotech

Vital Therapies Announces Workforce and Cost Reduction Plans to Conserve Capital for a Possible New Clinical Trial

SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced a workforce reduction of approximately 30% and plans to institute across the board expense reductions to conserve capital. The Company expects to record personnel-related severance charges of $1.2 million, primarily in the quarter ending September 30, 2015. “As we evaluate our next steps, it is necessary to conserve cash while we continue our analysis of the VTI-208 clinical trial data to possibly support the design and implementation of a new clinical trial

Globe Newswire

The Cooper Companies Announces Third Quarter 2015 Results

PLEASANTON, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) — The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal third quarter ended July 31, 2015. Revenue increased 7% year-over-year to $461.7 million. CooperVision (CVI) revenue up 10% to $385.5 million. CooperSurgical (CSI) revenue down 8% to $76.2 million. GAAP earnings per share (EPS) $0.91, down 89 cents or 49% from last year’s third quarter. Non-GAAP EPS $1.97, down 3 cents or 2% from last year’s third quarter. See “Reconciliation of GAAP to Non-GAAP Results” below. Commenting on the results, Robert S. Weiss, Cooper’s president and chief executive officer said,

Spectranetics Names Stacy McMahan Chief Financial Officer

COLORADO SPRINGS, Colo., Aug. 27, 2015 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) today announced that Stacy McMahan has been named Chief Financial Officer, effective September 28, 2015. In this role, Ms. McMahan will report directly to Scott Drake, President and Chief Executive Officer. Ms. McMahan has more than 25 years of finance leadership experience, including Chief Financial Officer and Vice President of Finance with responsibility for global, treasury, tax, internal audit, and decision support groups of high-profile public companies. Ms. McMahan currently serves as Senior Vice President, Chief Financial Officer and Treasurer of MSA Safety Incorporated (NYSE:MSA). Prior to

Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015

SOUTH SAN FRANCISCO, Aug. 27, 2015 (GLOBE NEWSWIRE) — Portola Pharmaceuticals (Nasdaq: PTLA) today announced that results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology (ESC) 2015 Congress in London, U.K. The study assessed the activity of andexanet alfa in reversing anticoagulation and reducing bleeding in a validated animal model using Daiichi Sankyo’s oral, once-daily, direct Factor Xa inhibitor edoxaban as the anticoagulant. Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of Factor

Blog

QLT and InSite Vision Agree on Amended and Restated Merger Agreement

VANCOUVER, British Columbia, Aug. 27, 2015 (GLOBE NEWSWIRE) — QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT”) today announced that it has entered into an Amended and Restated Merger Agreement with InSite Vision Incorporated (OTCBB:INSV) (“InSite Vision”), pursuant to which QLT will acquire InSite Vision in a share-for-share transaction. The revised merger consideration will be payable in QLT common shares based on an exchange ratio equal to 0.078x of a QLT common share per share of InSite common stock, subject to two adjustment mechanisms. First, the merger consideration will include a “collar” mechanism, which provides that the exchange ratio will be adjusted so

Photo Release — Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey

NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) — Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the tour, visitors were taken throughout the Alferon® and Ampligen® manufacturing suites and also via our Research and Development labs, where there has been a significant amount of resources spent on trying to find a biomarker for Ampligen® to treat Chronic Fatigue Syndrome (CFS). A photograph of the Research and Development facility is available for viewing on our website at www.Hemispherx.net. A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=35609 Thomas Equels,